comprehensive -WSS

comprehensive

author：hotspot 2025-09-29 01:36:07 - browse：49

RHONA WISE/AFP via Getty Images

WASHINGTON — Drugmakers are doing everything to tap the bottomless well of demand for new obesity drugs, and they might get some government help. The agency that regulates Obamacare insurance is considering a technical change that would require insurers to cover obesity drugs in a market of more than 20 million Americans.

Weight loss drugs are a blessing for patients, a boon for drugmakers, and a potentially huge expense for insurers and taxpayers. Insurers have been slow to cover the drugs, called GLP-1 agonists, and without insurance, it costs upward of $16,000 annually for a drug that must be taken indefinitely.

There is a lot of demand for the drugs, but there are barriers to coverage. Medicare by law is prohibited from paying for obesity drugs. State Medicaid programs don’t have to cover them, so most don’t.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： State of the Union pitch: Bigger Medicare drug price negotiations

focus

explore

WSS

Medicare drug price negotiation hearing pits pharma v Biden admin

Sarepta Duchenne therapy fails to meet primary endpoint in trial

Readout Newsletter: BridgeBio, Akero, and human embryo models

A new approach to psychiatric drug development

How neuroscience research could help beat back brain cancer

The health care issue Democrats can’t solve: hospital reform

focus

comprehensive

Wikipedia

United colonoscopy coverage change 'may cost lives,' doctors say

Prime Medicine says its gene editing passes test in monkeys

Duchenne breakthrough therapy leaves behind pioneering families

The public health thinking behind the CDC’s new Covid guidance

Tori Bowie and the unacceptable rates of Black maternal death

Key Senate panel to consider PBM, drug pricing reform package

Walensky prepares to leave CDC — and Congress — behind

Coloradans with cystic fibrosis could lose access to Trikafta

Duchenne breakthrough therapy leaves behind pioneering families

Longer MASH drug regimen improved liver, Akero study finds

explore

$1 billion proposal to grow Boston, Massachusetts biotech

Medicare drug price negotiation continues, as pharma counteroffers

Prime Medicine says its gene editing passes test in monkeys

Key Senate panel to consider PBM, drug pricing reform package

What is microchimerism and how does it affect maternal health?

What is microchimerism and how does it affect maternal health?

focus

leisure time

explore

Wikipedia